Explore the vast range of titles available.

BackgroundClot composition plays a key role in the pathophysiology of Acute Ischemic Stroke (AIS) and impacts the effectiveness of treatments such as thrombolysis and mechanical thrombectomy (MT). Developing an electrochemical impedance spectroscopy (EIS) based device to identify clot characteristics could improve stroke treatment outcomes. This study aims to estimate the red blood cell (RBC) and platelet content in extracted AIS clots and explore EIS’s relevance to clinically important parameters, including stroke etiology and First Pass Effect (FPE).MethodsA total of 508 clots from 426 MT patients at five stroke centers in France, Japan, Serbia, and Spain (February 2021–2024) were analyzed in the Clotbase International Registry. EIS was performed on retrieved clots, followed by Martius Scarlet Blue staining and CD42b immunohistochemistry. EIS based models to quantify RBCs and platelets were designed using a development dataset (n=309), validated on a blinded dataset (n=199), and combined in a full dataset (n=508). Components (median interquartile range (IQR)) were quantified, correlating RBC and platelet percentages with impedance and clinical parameters.ResultsCorrelations between content as determined by EIS and histology were validated in a blind dataset for RBCs (r=0.7, P<0.0001) and platelets (r=0.5, P<0.0001). Similar correlations were observed in the full dataset. Large-artery atherosclerosis clots had significantly higher RBC (46.0% (25.7–67.7)) and lower platelet content (31.7% (22.4–42.7)) compared with cardioembolic (RBCs: 34.9% (14.0–56.2); platelets: 36.5% (26.7–51.0)) and cryptogenic (RBCs: 31.5% (17.4–63.6); platelets: 37.8% (28.4–50.8)). FPE was associated with significantly higher RBC (40.0% (25.6–55.4) vs non-FPE: 31.2% (6.6–50.2)) and lower platelet content (42.0% (32.0–54.0) vs non-FPE: 47.7% (30.6–65.0)), confirmed by histology.ConclusionEIS of RBCs and platelets provide an accurate assessment of clot composition, correlating strongly with histology. EIS holds the potential to deliver clinically relevant information on clot characteristics at the point of care.

Metabolic encephalopathy (ME) represents a syndrome of temporary or permanent disturbance of brain functions that occurs in different diseases and varies in clinical presentation. It can be manifested in a range from very mild mental disorders to deep coma and death. Clinically, it is characterized by a variety of psychiatric and neurological symptoms and signs. The most common causes of ME are: hypoxia, ischemia, systemic diseases and toxic agents. ME is the most frequent in elderly people who have previously been exhausted by chronic illnesses and prolonged stay in bed. ME is a very common complication in patients treated in intensive care units. Treatment and prognosis of the disease are varied and depend on aetiology, as well as on the type and severity of clinical presentation. Mortality of patients with septic encephalopathy ranges from 16-65%, while the one-year survival of patients with encephalopathy and liver cirrhosis is less than 50%.